Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fulcrum Therapeutics (FULC) Restructuring Costs (2022 - 2024)

Fulcrum Therapeutics (FULC) has 2 years of Restructuring Costs data on record, last reported at $2.1 million in Q3 2024.

  • On a quarterly basis, Restructuring Costs changed N/A to $2.1 million in Q3 2024 year-over-year; TTM through Dec 2025 was $2.1 million, a 0.0% change, with the full-year FY2024 number at $2.1 million, changed N/A from a year prior.
  • Restructuring Costs reached $2.1 million in Q3 2024 per FULC's latest filing, up from -$38000.0 in the prior quarter.
  • Over the last five years, Restructuring Costs for FULC hit a ceiling of $2.1 million in Q3 2024 and a floor of -$38000.0 in Q4 2022.